- Tipos de Cáncer
Tipos de Cáncer
Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.A a la Z - Tratamiento
Tratamiento del Cáncer
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
- Riesgo de concer y prevencion
- Drogas de Cáncer
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
- Lidiando
Lidiando con el Cáncer
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
- Profesionales de la salud
- Estudios Clínicos
Notas para enfermeros 
¿Cuál es mi riesgo? k? 
OncoPilot: Manejando su experiencia del cáncer 
OncoLink Cancer Blogs
Community Events Calendar 
Abramson Cancer Center 
NCI CANCERLIT® Search: Wilms' Tumor Gene (WT1) - March 2002
National Cancer Institute®
Ultima Vez Modificado: 1 de marzo del 2002
Table of Contents
1
UI - 11547357
AU - Menssen HD; Brandt N; Leben R; Muller F; Thiel E; Melber K
TI -
Measurement of hematological, clinical chemistry, and infection
parameters from hirudinized blood collected in universal blood sampling
tubes.
SO - Semin Thromb Hemost 2001 Aug;27(4):349-56
AD - Dept. III Hematology, Oncology and Transfusion Medicine, Benjamin
Franklin Hospital, Freien Universitat, Hindenburgdamm 30, 12203 Berlin,
Germany. hmenssen@zedat.fu-berlin.de
Hirudin, the anticoagulatory polypeptide of the leech Hirudo
medicinalis, strongly inhibits thrombus formation by specifically
interacting with thrombin. For diagnostic purposes, hirudin should be
superior to other anticlotting compounds because it only minimally
alters the mineral, protein, and cellular blood constituents. To test
this hypothesis, hirudinized and routinely processed venous blood from
80 healthy volunteers and patients was subjected to a variety of
automated blood tests. A strong correlation was found between the
results of automated complete blood counts obtained from
K(2)-ethylenediaminetetraacetic acid (EDTA) anticoagulated and
hirudinized blood (1000 antithrombin units [ATU] hirudin/ml). In
addition, clinical chemistry and serological infection parameters
(asparlat amintransferase [ASAT], lactate dehydrogenase [LDH], sodium,
and so on, and antibodies against hepatitis B and C and human
immunodeficiency virus [HIV]1/2, respectively) correlated well when
measured in serum as compared with hirudinized plasma. Contrary to
single clotting factors, global coagulation parameters (activated
partial thromboplastin time [aPTT], prothrombin time [PT]) could not be
measured in hirudinized blood. Recombinant hirudin neither interfered
with immunophenotyping of mononuclear cells using FACScan analysis, nor
did it alter the detection of Wilms' tumor gene expression by RT-PCR
technology even at high doses (5000 ATU hirudin). Thus, a
hirudin-containing blood sampling tube can be designed as a universal
blood sampling tube (UBT) for testing the majority of diagnostic blood
parameters.
2
UI - 11880727
AU - Dome JS; Coppes MJ
TI -
Recent advances in Wilms tumor genetics.
SO - Curr Opin Pediatr 2002 Feb;14(1):5-11
AD - Department of Hematology and Oncology, St. Jude Children's Research
Hospital, Tennessee 38105-2794, USA. jeff.dome@stjude.org
The past decade has witnessed substantial growth in our knowledge of the
genes and loci that are altered in Wilms tumor. Although Wilms tumor was
one of the original paradigms of Knudson's two-hit model of cancer
formation, it has become apparent that several genetic events contribute
to Wilms tumorigenesis. Recent research has identified targets and
regulators of the first Wilms tumor gene, WT1, has uncovered several
candidate genes at the second Wilms tumor locus, WT2, and has identified
two familial Wilms tumor loci, FWT1 and FWT2. The recent discovery of
activating beta-catenin mutations in some Wilms tumors has also
implicated the Wnt signaling pathway in this neoplasm. Recurrent
abnormalities of other loci, including 16q, 1p, and 7p, have indicated
that these sites may harbor Wilms tumor genes. An enhanced understanding
of these and other genetic lesions will provide the foundation for novel
targeted Wilms tumor therapies.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
